Corridor Pharmaceuticals, Inc.

Corridor Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on developing and commercializing therapeutic small molecule inhibitors of arginase, an enzyme that competes with endothelial nitric oxide synthase for l-arginine, a common substrate. The company's arginase also produces ornithine, which elevates polyamine levels, stimulates cell division, and contributes to hyperplasia and fibrosis. Founded in 2007 and based in Lutherville, Maryland, the company was originally known as Arginetix, Inc., before changing its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. Corridor Pharmaceuticals, Inc. is pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies. The company has received a $1.56M Debt Financing investment on January 31, 2013, demonstrating interest and confidence from the investment community in its potential to make significant strides in the biotechnology and healthcare industries.